Active — Not RecruitingNot Applicable

Perioperative Management of Factor Xa Inhibitors

South Korea2,500 participantsStarted 2020-08-04

Plain-language summary

This study aims to analyze the safety and effectiveness of the discontinuation/resumption protocol of factor Xa inhibitors before and after invasive procedures/surgeries in non-valvular atrial fibrillation patients who are at risk of minor bleeding in actual clinical settings

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged \>20 years * With rivaroxaban, apixaban, or edoxaban * History of non-valvular atrial fibrillation * Scheduled minor bleeding risk procedure(s) (dental procedure, cataract/glaucoma surgery, diagnostic GI endoscopy) Exclusion Criteria: * Pregnancy * With rivaroxaban or edoxaban at afternoon * Mental disorder * Contraindication to rivaroxaban, apixaban, edoxaban * Moderate or severe valvular heart disease, or with prosthetic heart valves * With antiplatelet drugs * History of systemic embolism or ischemic stroke within the last 12 months * scheduled therapeutic endoscopic procedure(s)

What they're measuring

30-day major bleeding

Timeframe: Within 30 days after the operation/procedure

Trial details

NCT IDNCT05801068

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-15

View on ClinicalTrials.gov More Atrial Fibrillation trials